Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma.
We report a case showing the long-term clinical benefit of the continued use of gefitinib in a patient with asymptomatic progression of lung adenocarcinoma harboring an exon 19 deletion of the epidermal growth factor receptor gene. Although follow-up studies showed smoldering progression of metastatic lesions, continued treatment with gefitinib controlled pulmonary adenocarcinoma for more than six years.
Chonnam National University Hwasun Hospital and Chonnam National University Medical School Hwasungun, South Korea.
Hayoung
H
Choi
Chonnam National University Hwasun Hospital and Chonnam National University Medical School Hwasungun, South Korea.
Jinsun
J
Chang
Chonnam National University Hwasun Hospital and Chonnam National University Medical School Hwasungun, South Korea.
Hong-Joon
HJ
Shin
Chonnam National University Hwasun Hospital and Chonnam National University Medical School Hwasungun, South Korea.
Cheol-Kyu
CK
Park
Chonnam National University Hwasun Hospital and Chonnam National University Medical School Hwasungun, South Korea.
In-Jae
IJ
Oh
Chonnam National University Hwasun Hospital and Chonnam National University Medical School Hwasungun, South Korea.
Kyu-Sik
KS
Kim
Chonnam National University Hwasun Hospital and Chonnam National University Medical School Hwasungun, South Korea.
Young-Chul
YC
Kim
Epidermal growth factor receptor; gefitinib; non-small cell lung carcinoma